Magazine Article | May 2, 2022

A New Model For A New Era Of Psychedelic Therapy

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

By 2031, the Multidisciplinary Association for Psychedelic Studies, or MAPS, aims to have treated 1 million post-traumatic stress disorder (PTSD) patients with 3,4-methylenedioxymethamphetamine (MDMA), a psychoactive drug also known by the street names Ecstasy or Molly. Designated by the FDA as a Breakthrough Therapy in 2017 and currently undergoing Phase 3 trials in the U.S., Canada, and Israel, following the completion of an initial Phase 3 study in 2021, MDMA is the closest drug to FDA approval amid a rapidly expanding field of psychedelic medicines.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: